What is Codex BioSolutions?
Codex BioSolutions, based in Maryland, is an advanced biotechnology company specializing in high-throughput solutions for drug discovery. The company is distinguished by its patented ACTOne-based phosphodiesterase (PDE) and G-protein coupled receptor (GPCR) cell lines, which are instrumental in facilitating efficient screenings of novel compounds within live cell environments. Their service offerings encompass compound screening, assay development, and strategic collaborations with pharmaceutical entities and research institutions. Furthermore, Codex BioSolutions develops proprietary biochemical assay kits and specialty dyes, all engineered to enhance and expedite the discovery processes for their clientele.
How much funding has Codex BioSolutions raised?
Codex BioSolutions has raised a total of $42K across 1 funding round:
Debt
$42K
Debt (2021): $42K with participation from PPP
What's next for Codex BioSolutions?
With the recent substantial expansion capital, Codex BioSolutions is poised to scale its operations and further develop its innovative drug discovery platforms. This strategic investment at a significant Series B/C stage suggests a focus on broadening market reach, enhancing technological capabilities, and potentially forging new key partnerships within the pharmaceutical and biotech industries. The company's trajectory indicates a commitment to advancing the efficiency and effectiveness of compound screening and assay development, aiming to accelerate the pipeline for new therapeutic agents.
See full Codex BioSolutions company page
